Vol.

No.

December 11, 2015Dec 11, 2015

Free

DOWNLOAD THE PDF

Cover Story

Core Grants of Newer, Smaller Centers Slated to Get Immediate Funding Boost

By Paul Goldberg

NCI is implementing a less draconian formula for increasing the core grants of newer cancer centers.

Capitol Hill

NIH Looks For $1-2 Billion Raise in FY 2016, as Congress Approaches Another Deadline

By Matthew Bin Han Ong

Guest Editorial

The Academic Difference

By George J. Weiner

ACS and ASCO Jointly Publish Breast Cancer Survivorship Guideline for Primary Physicians

In Brief

Rodriguez-Galindo to Lead St. Jude International Outreach

Daniel Simon named president of UH Case Medical Center

Terrill Jordan named president and CEO of Regional Cancer Care Associates

Gustave Roussy institute recruiting young doctors

Baylor to collaborate with Biocept on blood-based cancer tests

Drugs & Targets

FDA Approves Alecensa for ALK-Positive NSCLC Patients

FDA approves Vistogard for emergency treatment of certain chemotherapy overdoses

FDA clears cooling cap for preventing hair loss during chemotherapy

EMA grants orphan designation ot Debio 1143

Amgen submits expanded application for Kyprolis in the EU

AstraZeneca and Voluntis to test digital support service in ovarian cancer trials

Eli Lilly and Merck to collaborate on abemaciclib-Keytruda phase I trial

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 43 - November 15, 2024

Core Grants of Newer, Smaller Centers Slated to Get Immediate Funding Boost

NIH Looks For $1-2 Billion Raise in FY 2016, as Congress Approaches Another Deadline

The Academic Difference

ACS and ASCO Jointly Publish Breast Cancer Survivorship Guideline for Primary Physicians

In Brief

Rodriguez-Galindo to Lead St. Jude International Outreach

Daniel Simon named president of UH Case Medical Center

Terrill Jordan named president and CEO of Regional Cancer Care Associates

Gustave Roussy institute recruiting young doctors

Baylor to collaborate with Biocept on blood-based cancer tests

Drugs & Targets

FDA Approves Alecensa for ALK-Positive NSCLC Patients

FDA approves Vistogard for emergency treatment of certain chemotherapy overdoses

FDA clears cooling cap for preventing hair loss during chemotherapy

EMA grants orphan designation ot Debio 1143

Amgen submits expanded application for Kyprolis in the EU

AstraZeneca and Voluntis to test digital support service in ovarian cancer trials

Eli Lilly and Merck to collaborate on abemaciclib-Keytruda phase I trial

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login